Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture

Maria Angeles Marques-Torrejon¹, Ester Gangoso¹, Steven M. Pollard¹,*

¹MRC Centre for Regenerative Medicine and Edinburgh Cancer Research UK Cancer Centre, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK.

* Corresponding author:
Steven Pollard: steven.pollard@ed.ac.uk Tel: +44 (0)131 6519544

Keywords: Glioblastoma, adult brain, niche, slice culture, quiescence, proliferation
Abstract

Glioblastoma (GBM) is an aggressive incurable brain cancer. The cells that fuel the growth of tumours resemble neural stem cells found in the developing and adult mammalian forebrain. These are referred to as GBM stem cells (GSCs). Similar to neural stem cells, GSCs exhibit a variety of phenotypic states: dormant, quiescent, proliferative and differentiating. How environmental cues within the brain influence these distinct states is not well understood. Laboratory models of GBM can be generated using either genetically engineered mouse models, or via intracranial transplantation of cultured tumour initiating cells (mouse or human). Unfortunately, these approaches are expensive, time-consuming, low-throughput and ill-suited for monitoring of live cell behaviours. Here we explored whole adult brain coronal organotypic slices as an alternative model. Mouse adult brain slices remain viable in a serum-free basal media for several weeks. GSCs can be easily microinjected into specific anatomical sites ex vivo and we demonstrate distinct responses of engrafted GSCs to diverse microenvironments in the brain tissue. Within the subependymal zone – one of the adult neural stem cell niches – injected tumour cells could effectively engraft and respond to endothelial niche signals. Tumour transplanted slices were treated with the anti-mitotic drug temozolomide as proof-of-principle of the utility in modelling responses to existing treatments. Engraftment of mouse or human GSCs onto whole brain coronal organotypic brain slices therefore provides a simplified, yet flexible, experimental model. This will help to increase the precision and throughput of modelling GSC-host brain interactions and complements ongoing in vivo studies.
Introduction

Glioblastoma multiforme (GBM) is a highly aggressive malignant brain tumour. It is the most malignant form of glioma. Standard treatments involve combined surgery, radiotherapy, and adjuvant temozolomide (TMZ) chemotherapy (Stupp et al., 2005), but survival rates are extremely poor. Various obstacles hamper development of effective therapies, including: pervasive tumour cell infiltration, genetic heterogeneity (both intra- and inter-tumoural), therapeutic resistance, blood-brain barrier, and lack of biological understanding of the disease. Improved experimental models will help address some of these issues.

GBM tumour cells disseminate widely across many brain regions, often following neuronal tracts and vasculature. Cells are therefore exposed to diverse microenvironments, such as specific repertoires of cell matrix and growth factors, or cellular niches (e.g. perivascular, invasive or hypoxic). These environmental cues steer glioma stem cell (GSC) fate, affecting quiescence, proliferation, survival and differentiation pathways (Codrici et al., 2016; Gilbertson and Rich, 2007; Okawa et al., 2016a). Modelling these various tumour cell-host brain interactions is therefore vital for improved understanding of disease biology and development of new therapeutic strategies.

GSCs highjack many molecular programs that regulate neural stem cell self-renewal. Improved understanding of mechanisms controlling neural stem cell fate will therefore likely lead to new insights into the disease and identification of critical therapeutic targets. Neural stem cells (NSCs) are located within the lateral walls of the forebrain ventricles in a region known as the subependymal zone (SEZ) (Doetsch et al., 1999). The SEZ provides a specific niche that sustains the NSCs throughout life. NSCs are exposed to a myriad of cell-cell signals and ECM interactions that steer
NSC fate, such as: endothelial cells, ependymal cells, and cerebral spinal fluid (Mirzadeh et al., 2008; Shen et al., 2008; Silva-Vargas et al., 2016). Understanding how tumour cells respond to normal SEZ is important, as this might be region harboring a reservoir of tumour cells (Piccirillo et al., 2015).

Patient-derived GSCs can be routinely expanded in vitro using culture media developed for NSCs, either in suspension or adherent culture (Galli et al., 2004; Hemmati et al., 2003; Lee et al., 2006; Pollard et al., 2009; Xie et al. 2015). Orthotopic transplantation of freshly isolated or cultured GSCs into the adult rodent brain using stereotaxic surgery is the ‘gold standard’ method to test tumour-initiating potential. However, animal surgery and transplantation deep into the brain provides limited scope to track live cell behaviours. Typically, these experiments take weeks or months and are non-trivial to setup. They do not enable direct inspection of single cell behaviours such as invasion, monitoring of quiescence and differentiation or responses to genetic or chemical perturbations. These practical constraints have limited the scale and scope of studies aimed at understanding and treating gliomas. To address this, we explored the utility of organotypic slice cultures to monitor GSC-host interactions.

Organotypic brain slice cultures were first developed in the 1960’s (Crain, 1966). Since then they have been widely used by neuroscientists, particularly in studies of neuronal function and circuits (reviewed in (Humpel, 2015). Microdissected regions are cultured above a semipermeable membrane in a cell culture insert and exposed to serum containing media from below. An example of their successful use are studies using hippocampal slices cultures; this is widely deployed for studies of synaptic plasticity and memory (Gahwiler et al., 1997). Organotypic slice cultures overcome some of the difficulties of in vivo studies as they provide ex vivo access to brain tissue architecture, while still enabling direct observation and cell manipulations in the culture.
dish (Humpel, 2015). Slice cultures have also been used to explore the response of glioma cells to brain tissue, particularly to explore mechanisms of infiltration and migration. However, these have mainly used postnatal brain slices grown in serum or of mice harboring preexisting tumours (Minami et al., 2017; Matsumura et al., 2000; Jensen et al., 2016; Ohnishi et al., 1998).

Here, we report improved conditions enabling serum-free culture of adult coronal whole brain slices in a manner that enables tracking of GSC behaviors over several weeks. Our experimental approach provides a useful new strategy to explore GBM. This model bridges the ‘experimental gap’ between in vitro cell culture models and in vivo orthotopic transplantations. As an exemplar of the utility of this approach we confirm engraftment of GSCs around blood vessels in the slice culture and demonstrate how it can be used in preclinical studies of anticancer agents.

Results

Whole adult brain coronal slice cultures are viable for weeks in serum-free neural stem cell media

Most studies employing organotypic slice cultures use postnatal mice and dissect specific regions of the brain (e.g. hippocampus). However, GBM is predominantly a disease of adults and cells disseminate widely across all brain regions. We therefore focused on whole brain slices, reasoning that even short-term viability, for days or weeks, could provide a useful model for testing tumour cell-host brain interactions.
Adult brains were harvested from young adult mice (~4 weeks) and the olfactory bulbs and cerebellum were removed (Figure 1A and B). We generated whole-brain coronal sections using a vibratome to cut ~200µm slices at the level of the forebrain ventricle (6 slices per brain). Each section was placed on to a semi-permeable membrane culture insert and cultured in a six well cell culture plate (Figure 1B).

Established organotypic brain slice protocols require high levels of serum or growth factors. However, serum exposure will trigger astrocyte differentiation of NS cells (Conti et al., 2005)(Figure S1A-B). Culture media lacking serum or exogenous growth factors was therefore tested. This removes the risk of cell fate being primarily directed by additives in the culture media, rather than endogenous tissue-derived signals. Dying cells were identified at edges of the dissected region, using by propidium iodide (PI) staining (Figure 1C) and active Caspase 3 immunostaining (Figure 1D). Serum-free NS cell-permissive culture media could indeed support slices over several weeks (Figure 1C). By contrast in basal media with no N2 or B27 hormonal supplements the tissue became necrotic in days (Figure S1C).

Within the healthy coronal sections, we were able to detect BIII tubulin-expressing neuroblasts, gliotubes and choroid plexus, suggesting the tissue retained key features of the neurogenic niche (Figure 1E). In summary, whole brain coronal slices are viable for several weeks in serum-free media – much longer than we anticipated – thereby providing an opportunity to assess responses of transplanted GSCs.
Patient-derived glioblastoma stem cells engraft into the mouse SEZ and retain expression of quiescent NSC markers CD133 and CD9.

We next tested the potential of patient-derived human GSCs to engraft into the slices. G7-GFP cells have previously been shown to be highly invasive when transplanted into striatum of immunocompromised mice (Stricker et al., 2013). We tested different NS cell markers in vitro before depositing the cells: KI67, OLIG2, SOX2, NESTIN, CD9, and CD133 (Figure Supplementary 3A). We first tested microinjection of 10000 cells into the SEZ (Figure 2A). One week later using live cell imaging we noted large numbers of healthy GFP expressing cells successfully engrafted. After 2 weeks, slices were fixed and immunocytochemistry (ICC) confirmed cells were viable and ~10% were actively proliferating, based on Ki67 and Stem121 expression (Figure 2B). We next assessed the known cancer stem cell marker CD133 in the GFP cells after three weeks. Interestingly, CD133 expressing cells were identified in a subset of cells, suggesting that GSCs generate phenotypic heterogeneity in the slices (Figure 2C).

New molecular markers associated with quiescent NSCs have recently been uncovered using single cell RNA-seq approaches (Llorens-Bobadilla et al., 2015; Shin et al., 2015). The transmembrane glycoprotein tetraspin (CD9) was identified as a putative marker of qNSCs. The G7 cells within the SEZ in slices expressed CD9 (Figure 2D) after 21 days. We conclude that human GSCs can engraft, survive and proliferate in whole-brain slice co-cultures for at least 3 weeks, while retaining key cancer stem cell markers.
Patient-derived glioblastoma stem cells have distinct responses to region-specific adult brain microenvironments

We next compared how cells would respond in the SEZ versus other brain regions in terms of their proliferation and differentiation. Four distinct regions were tested: striatum, corpus callosum (CC), cortex and SEZ (Figure 3A). One week after microinjection into a lateral region of the CC, we noted many G7 cells aligning with and dispersing across the white matter tracts and displaying infiltrative morphology. PI staining of technical replicates was used to assess viability of CC and SEZ adjacent regions, and we did not observe any significant cell death in these regions (Figure 3B). Transplanted cells displayed reduced Ki67 and increased GFAP compared to cells deposited in parallel within the SEZ of the same slice (Figure 3C-D). Similar results were observed for cells within the cortex and striatum. Thus, slice cultures provide a convenient method to quickly assess responses of GSCs to the diverse anatomical microenvironments within the adult brain. This enables future exploration of various signals regulating cell fate within the SEZ niche.

Microglia in the adult brain are often activated during injury. In order to check whether there was pervasive, and/or region-specific activation of microglia in the slices, we assessed the activated microglia marker Ionized calcium binding adaptor molecule 1 (Iba1) using immunohistochemistry (Figure 3E). As expected, we noted activation; however, this was general at the surface of the slices and was not enriched in any specific region.
Mouse glioblastoma initiating cells engraft into the subependymal zone and can juxtapose to endothelial cells

To minimize disruption of the niche and to enable injection of smaller volumes/numbers of cells (~100 cells in ~40nl) we performed transplantation of cells using a microinjection pump connected to a pulled glass capillary (Figure 1A-B). This enabled more precise and localized injection into the walls of the lateral ventricle (Figure 4A). We used a previously characterised mouse tumour-initiating cell line, termed IENS-GFP (Ink4A/Arf<sup>−/−</sup> deleted plus EGFRvIII viral overexpression) (Bruggeman et al., 2007). These cells stably express GFP from a constitutive promoter. In vitro they express GSC markers such as Nestin, Sox2, Olig2 (Figure S2A). IENS cells generate aggressive infiltrative tumours when transplanted in vivo (n=4) (Figure S2B). These were preferred to human patient-derived G7-GFP, as these displayed brighter GFP and were smaller, reducing needle blockage and therefore distributing better at the injection site. Moreover, use of mouse glioma cells is appealing for future studies, as this enables interrogation of certain immune responses (e.g. microglia activation).

IENS cells were injected precisely into the SEZ through the wall of the lateral ventricle. Initially, they displayed a remarkably specific localization and even distribution throughout the SEZ (Supplementary Movie 1). We next compared cellular responses to the SEZ versus in other brain regions, scoring proliferation and astrocyte differentiation or quiescence (type B-like) (Ki67 and GFAP). Four distinct regions were tested: cortex, corpus callosum (CC), striatum and SEZ (Figure 4B-4C). As was the case with the human transplanted cells, we noted increased proliferation in the SEZ (Figure 4B-C).
When imaged using confocal microscopy we noted juxtaposition of GSCs with endothelial cells (Figure 4E and Supplementary movie 2). The close interactions and extended processes along vessels is reminiscent of previous work reporting the importance of this as niche for NSCs (Kokovay et al., 2010). 5 days after microinjection, the rate of proliferation was around 40-50% (measured as Ki67+ cells of the GFP cells). ~15% began to express high levels of the astrocytic marker GFAP (Figure 4F). Cells remained viable for two weeks and showed evidence of proliferation and local infiltration into surrounding regions (n=3) (Figure 4D and Movie 1 and Movie 2).

Glioblastoma stem cells engrafted into brain slices respond to the cytostatic effects of temozolomide

Whole brain slices harbouring GSCs provide a convenient method to explore the effects of pharmacological agents in an easier and higher throughput experimental system than live animals. To demonstrate proof-of-principle of its potential utility as a preclinical assay we first explored anti-mitotic treatments. Ara-C or Temozolomide (TMZ) have been widely used to assess neural stem cell behavior during regeneration and repair (Daynac et al., 2016; Doetsch et al., 1999). TMZ is the standard chemotherapy given to many patients with GBM. Both agents drive DNA damage and disrupt proliferation of tumour cells. TMZ is a DNA alkylating agent that often induces G2/M arrest.

Responses were scored using immunocytochemistry for two markers: gamma-H2AX for double strand breaks, and p53 as an indicator of DNA damage response (Figure 5A). We first tested activity of each factor at previously reported effective doses on IENS-GFP cultures in vitro, TMZ at 1,10 and 100µM and AraC at 1 and 2 µM.
We next treated slices harbouring successfully engrafted IENS-GFP cells after 3 days with 100µM TMZ or 1µM Ara-C (24 hrs). Slices were then assessed for Ki67 and pH3 using immunocytochemistry (Figure 5E-F). In each condition, we observed a reduction in Ki67 and GFP double positive cells (100µM TMZ: 13%, 1µM Ara-C: 20%). Untreated control slices retained ~30% double positive (Figure 5E-F). To determine the degree of cell death by apoptosis following treatment, we scored active Caspase 3 (Figure 5G, 5H). Cytostatic responses of tumour cells to drug treatment within slice co-cultures can therefore easily be monitored.

**Discussion**

Primary in vitro cell cultures of human glioblastoma stem cells are an important disease-relevant experimental model system. However, an obvious limitation of dissociated cell cultures is the difficulty in modelling interactions with the complex tissue environment. Here we have demonstrated that brain tumour cell interactions with host brain tissue can be explored effectively by injection of cells onto adult brain slice cultures and co-culture.

Past studies have typically used microdissected regions of postnatal brain slices cultured in the presence of serum, as this is necessary to support long term viability (months) (Ullrich et al., 2011). Yet our observations indicate that whole brain adult coronal slices are viable in serum free media for several weeks. This is long enough to permit tracking of tumour-host tissue interactions, such as interactions with endogenous stem cell niches or white matter tracts and enables us to expose GSCs to brain tissue interactions. These methods therefore provide a tractable ex vivo model system that can now be exploited in both basic and translational studies of GBM. It is an approach that reduces the need for laborious and expensive mouse
breeding or stereotaxic surgery, thereby increasing the speed and experimental throughput.

Avoiding exposure of transplanted cells to high levels of serum within traditional slice cultures methods enables a more physiological signaling environment to be maintained. This reduces the degree of serum-induced astrocyte differentiation which has hampered our previous studies (unpublished observations). Although serum free media has been used to maintain whole-mount tissue explants of the mouse SEZ for up to 16 hours (Kokovay et al., 2010), to our knowledge longer term survival of whole coronal brain slices in serum free media has not be reported or used in studies of GSCs. Surprisingly, we found that serum wasn’t needed in order to maintain healthy slices of the whole adult coronal brain, at least for 1 to 2 weeks. Slices seem viable in the basal neural media with no exogenous growth factors and supplemented only with N2 and B27 hormonal supplements.

With viable coronal adult brain slices we were able to assess the responses of both mouse and human GSCs to distinct anatomical regions over several weeks of co-culture. As each mouse can provide up to 5 or 6 slices and cells can easily be injected in a spatially-restricted manner. Live cell imaging can be performed to track dynamic cell behaviors, such as interactions with blood vessels, infiltration or division (Supplementary Movie 1). For example, GBM cells infiltrate widely, and have been shown to use both neuronal tracts and blood vessels as a substrate and guide for migration (Farin et al., 2006; Krusche et al., 2016). The slice cultures reported here should be useful in probing such distinct cellular mechanisms of infiltration. Another future potential application will be the tracking of cell lineage reporters, especially with the advent of genome editing tools that can be applied in GBM (Bressan et al., 2017). This will also help shed light on mechanisms of GSC dormancy and quiescence. One limitation of the method is that inevitably we trigger cell death and activation of the
microglia through the slicing procedure itself; however, we did not notice region specific differences across the slice, and most were located at the cell surface. As the slices are relatively thick (~200µm) and tumour cells infiltrate deep into the slice, it maybe possible still explore tumour-cell microglia interactions.

We were particularly interested in assessing tumour cell responses within the SEZ. The SEZ provides a specific niche that sustains the NSCs, and a repertoire of cell-cell signals and ECM interactions that steer NSC fate, including: endothelial cells, ependymal cells, and cerebral spinal fluid (produced by the choroid plexus) (Mirzadeh et al., 2008; Shen et al., 2008; Silva-Vargas et al., 2016). Gliomas may frequently arise from endogenous neural stem cells, or serve as a reservoir of cells that in some patients can drive relapse (Piccirillo et al., 2015). We noted key elements of the healthy SEZ microenvironment were viable – ventricle, gliotubes, RMS, ependymal cells. Importantly, endothelial cells within this region are thought to serve as an important niche signal; indeed we noted close interactions between vessels and tumour cells, with extended processes and wrapping around the vessel, highly reminiscent of normal NSC interactions (Kokovay et al., 2010).

We demonstrated that human GSCs can engraft effectively into the tissue of SEZ. CD133 is expressed by many glioma stem cells. We observed expression of this marker in both the mouse and human GSCs. Another more recently proposed marker of the quiescent astrocytes is CD9. We and others have recently found increased levels of CD9 in GSCs compared to normal NSCs (Okawa et al., 2016b; Podergajs et al., 2015). We found that CD9 is indeed retained on cells within the SEZ, suggesting ‘stemness’ may be effectively retained. As anticipated, reduced proliferative responses were noted when cells were deposited at other anatomical sites, such as corpus callosum. Distinct brain regions clearly will have significant differences in their ability to influence tumour cell proliferation and differentiation.
A limitation of this slice culture approach is the difficulty of achieving viable slice cultures past 3 weeks. Although we did note some loss of some tissue integrity past three weeks, we did not specifically push this further or search for modified culture regimes. This might be important to resolve in future, particularly for slower growing human GSCs, which take weeks to months to start initiate tumour growth in live xenografted mice. This alongside the damage and immune activation triggered by the slice procedure itself and inherent disadvantages that means this assay cannot replace either GEMMs or intracranial transplantation in live mice.

A multitude of new agents are emerging that will require effective preclinical studies. There is bottleneck and huge cost associated with testing of new pharmacological agents in living animals before these can enter clinical trials for GBM. The methods outlined here offer a potential complementary assay to in vivo testing. To demonstrate potential utility as preclinical model, we tested the responses of cells to antimitotics (AraC and TMZ). TMZ is used in many GBM, yet our understanding of how it influences distinct compartments of the GSC and resistance mechanisms remains limited. Future candidate drugs will need to be explored alongside TMZ to search for the most effective doses and regimes. Thus, the methods reported here should therefore prove useful in prioritising and triage of candidate therapeutic agents moving through preclinical studies.

In conclusion, the organotypic method presented here provides a simplified model for assessing responses of GSCs to various brain anatomical sites and microenvironments. This will therefore complement existing in vitro and in vivo models, helping to prioritise genes and pathways controlling key malignant properties of GBM and aiding the preclinical testing of new anti-cancer agents.
Materials and Methods

Organotypic adult brain slice culture.

5-8 week old C57BL/6 mice were used. More consistent results were often obtained using the younger animals – particularly the viability after 2-3 weeks culture. The brain was removed from the skull and transferred to a 10cm² tissue culture dish with sterile PBS and placed on ice (Figure 1A-1B). Cerebellum and olfactory bulb were removed (Figure 1B) and remaining forebrain transferred into a 35mm² dish with pre-warmed 3% SeaPlaque™ agarose (50100 Lonza) (Figure 1A-1B). Upon cooling in ice the block was removed and cut using a scalpel into a ~ 2cm cube around the brain. Before starting to cut a 6 well plate was prepared: in each well we introduced one cell culture insert (PICMORG50 Millicell) and added bellow it 1mL of culture media in serum-free basal NS cell media, DMEM:F12 supplemented with N2 and B27 (Life Technologies). The embedded brain was placed in the circular vibratome plate with glue (Figure 1A-1B). The vibratome (Leica VT1000 S) plate was fixed in the platform and was filled with PBS with penicillin-streptomycin (Gibco 15140-122 1:100). 250 µm thick slices were cut, with vibrating frequency at 8 and speed to 3. Each slice was transferred using a small brush onto the top of a Millipore culture insert (Figure 1A-1B). Six slices were cut per animal along the SEZ. The platform has to be maintained cooled all the time. We obtained six slices around the forebrain ventricle. The 6 well plate was placed in an incubator at 37°C + 5% CO₂. Incubate slices 24-48 hours prior to cell transplantation.
Glioblastoma cancer stem cell transplantation onto brain slices

G7 human GBM stem cell cultures have been previously described (Stricker et al., 2013). For human cell transplants a standard Gilson pipette was used to deposit 0.2 µl of cells onto the centre of the striatum, the typical injection site when performing stereotaxic surgery for tumour initiation assays. These cells engrafted well into the slice and their integration could be observed the following day.

IENS-GFP mouse cells were a gift from Dr. Lohuizen (Bruggeman et al., 2007). Both mouse and human GNS cells were grown using conditions previously described (Pollard et al., 2009). After centrifugation cells were harvested and resuspended in media at 100,000 cells/µl. Cells were used immediately for transplantation in the SEZ. Two different methods of cells injection were used. A manual using a p2 Gilson pipette was used to injected 0.5ul, while an auto-nanoliter injector (Nanoject II, Drummond Scientific Company) was used for 40-100nl injections. For the injector we use glass capillaries pulled using an automated needle puller (tip diameter, 10–20 μm; Drummond) (Figure 1B). 4000 cells were transplanted per injection. 20000 cells were transplanted when the P2 pipette was used. To facilitate engraftment and prevent wide dispersion of the 0.2 µl of cells, we used forceps to make a small indentation in the transplant site prior to delivery of the cells. Slices with cells were incubated at 37°C + 5% CO₂ for 7 days, with fresh NS cell media (no EGF or FGF-2) added every 2 days. Cell engraftment of the cells was observed 4 days after transplantation and cells could were monitored using a fluorescence stereo microscope (Leica M165 FC). For anti-mitotic treatments in the IENS-GFP in vitro, different doses of the cytosine arabinoside (AraC) (Sigma) was added to the complete media at different doses 1µM, 2uM and TMZ (Sigma) at 1uM, 10uM and 100uM for 24 hours. For anti-mitotic
treatments of IENS-GFP in the slices, the cells were growing in the brain slice for 3 days and the AraC was added to the complete media at different doses at 1µM and TMZ at 100µM for 24 hours.

**Immunocytochemistry**

Media was removed and exchanged for 1mL of freshly prepare 4% paraformaldehyde (PFA). 1-2 mL was also placed gently on top to cover the slice. After for 2 hours PFA was removed and brain slices were wash with PBS three times. Slices were transfer using a brush to a 24 well plate. Slices were incubated at room temperature 1 hour and a half in blocking solution (0.2% Triton X-100 and 3% Goat Serum; Sigma). Primary antibodies GFAP (G3893 Sigma 1:100), Ki-67 (RM-9106 Thermo Fisher 1:100), GFP (13970 Abcam 1:100), CD31 (14-0311-81 eBioscience 1:100), CD9 (14-0091-82, eBioscience 1:500), CD133 (MAB4310, Millipore 1:100), DCX (AB2253 Millipore 1:500), Nestin (1/10 Hybridoma Rat 401), stem121 (440410, Cellalartis 1:300), pH3 (50-9124-41, eBioscience 1:50), H2AX (phosphor S139) (ab81299, Abcam 1:50), Iba1 (NB-1-1028SS Novus 1:100), Olig2 (AB9610 Millipore 1:200), Sox2 (AB5603 Millipore 1:100), active 3 Caspase (ab2302 Abcam 1:100).

For H2AX staining cells were fixed with could fix the cells methanol-acetone 1:1 for 10 min run temperature. Positive cells were scored using the Fiji image analysis software. For IHC, the primary antibodies were incubated 2 days at 4ºC. After three washes with PBS, slices were incubated with with appropriate Alexa Fluor (Life technologies) secondary antibody and DAPI (D9542-SIGMA) with for 4-6 hours. Slices were washed three times and were mounting in a slide and immersed in FluoroSave™ Reagent
(345789 Calbiochem). Slices were examined with a confocal microscope (Leica TCS SP8). Propidium iodide (14289-25 CAYMAN) was used at 5ug/ml in PBS for 5 min and the tissue was analyzed under the fluorescent stereomicroscope. For Hematoxylin and eosin staining brain slices were fixed with 4% PFA for 1 hour. They were immersed in Harris Hematoxylin (Thermo-6765004) for 10 min and after washed in tap water. Following this, the slices were immersed 10 sec in 1% Acid –Alcohol and washed again in tap water. The brain slices were in tap water 30 sec and washed again in tap water. Finally, they were immersed in Eosin Y (Thermo-6766010) for 10s and washed once more. The brain slices were imaged using Leica stereomicroscope.

**Acknowledgements**

We are very grateful for the support provided for imaging from Bertrand Vernay (University of Edinburgh). MAMT was supported by a Postdoc EMBO Long-Term Fellowship. EG was supported by a Postdoc fellowship from Fundacion Ramon Areces (Spain). SMP is supported by a Cancer Research UK Senior Research Fellowship (A19778).
References


Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, B. W., Christopher, N., Zhang, W., et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391–403.


Figure 1 | Overall experimental strategy and tissue processing. (A) Summary of experimental procedure to generate slices. (B) Experimental steps in the harvesting, mounting, slicing and injection of brain tissue; (a) scissors, forceps and spatula are used to isolate and dissect the whole brain; (b) Image of whole adult mice brain on ice
following harvesting; (c) Dorsal image of whole brain following removal of the olfactory bulb (OB) and cerebellum; (d) Embedded brain in low melting agarose; (e) Attached brain to the support of the vibratome; (f) ~250µm coronal brain slice of placed onto a cell culture insert in a 6 well plate with neural stem cell basal media; (g) nanoinjector mounted on a micromanipulator used for injection of small volumes of cells, with mounted glass capillary (h), containing cell suspension; and (i) microinjection of cells into the SEZ of a coronal brain slice on the cell culture insert. (C) Top panel, viability of the tissue assessed using propidium iodide (PI) after 7, 14 and 21 days. Bottom panel, active-caspase 3 staining. Quantification of the mean intensity of the PI in the brain slices up to 21 days (right). (D) Immunocytochemistry following 7 days slice co-culture for: GFAP positive gliotubes (green left panel); B III tubulin neuroblasts (red middle panel) and choroid plexus (H&E; right). Nuclear counterstaining with DAPI in each (blue). SEZ: subependymal zone; CC, corpus callosum; LV; lateral ventricle, Sep: Septum. RMS; Rostral migratory stream. Scale bars: 100µm (left) and 10µm (right). N=3, Students t-test p < 0.05.
Figure 2 | Human patient-derived glioma stem cells engraft in adult mouse subependymal zone. (A) Direct microinjection of human line into adult SEZ and visualisation of engrafted live cells using a constitutive GFP reporter. Right panels are zoom of left panels. (B) Immunostaining for human specific cytoplasmic antigen (Stem121; yellow) and Ki67 (red) after 14 days. (C and D), Marker analysis after 21 days of ex vivo culture; (C) immunocytochemistry for CD133 (purple); (D) CD9 (red). Nuclear counterstaining with DAPI (blue). Scale bars: B = 50 µm and C,D = 20 µm.
Figure 3 | Differential proliferative responses to human glioma stem cells engrafted into different brain regions

(A) Live images of G7-GFP human glioma stem cells deposited into distinct regions of the same coronal brain slice after 7 days. (B) Immunocytochemistry for GFAP (yellow) and Ki67 (red) and GFP (green). CC: corpus callosum. (C) Quantification of the percentage of proliferating and differentiating cells (Ki67 and GFAP, respectively). (D) Immunocytochemistry for Iba1 (green) in different brain regions: CC, Cortex, Striatum, SEZ. Scale bars: B,D= 50 µm. N=3, Students t-test p<0.01.
Figure 4 | Glioma stem cells (GSC) in their niche. (A) (Left) Schematic of the experimental setup: co-culture of the GSC and the whole brain coronal sections.
Right, panoramic position of the GSC (green) in the SEZ after deposition. (B) 3D image showing the engraftment and infiltration of the IENS-GFP in the brain slice after 5 days. (C) 3D image with immunostaining of the IENS-GFP contacting with the blood vessels. GFP (green), CD31 (red) and nuclear counterstaining with DAPI (blue). Schematics of the interaction GSC with brain blood vessels. (D) Top panel: Panoramic view of IENS-GFP cells in SEZ. Immunostaining for GFP (green), Ki67 (white), GFAP (purple) and nuclear counterstaining with DAPI (blue). Bottom panel: Detail of the top one. Cells proliferating and expressing some GSC and astrocytic marker as GFAP and the proliferative marker Ki67. (E) Immunostaining for GFAP (yellow), Ki67 (red) and GFP (green) in the cells deposited in different parts of the brain slices. (F) Quantification of the percentage of GFAP and Ki67. In (C) cx, cortex; cc, corpus callosum; st, striatum; SEZ, subependymal zone; LV, lateral ventricle. Scale in (B) 20µm, (F) 20µm (G) 50µm (E) 100 µm. N=3, Students t-test p<0.01.
**A**

Con (DMSO)  | TMZ  | AraC
---|---|---

**B**

<table>
<thead>
<tr>
<th>Concentration (μM)</th>
<th>Mean Nuclear Intensity (H2AX foci)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>40 ± 10</td>
</tr>
<tr>
<td>1</td>
<td>50 ± 5</td>
</tr>
<tr>
<td>10</td>
<td>60 ± 6</td>
</tr>
<tr>
<td>100</td>
<td>70 ± 7</td>
</tr>
<tr>
<td>1</td>
<td>40 ± 4</td>
</tr>
<tr>
<td>2</td>
<td>30 ± 3</td>
</tr>
</tbody>
</table>

**C**

TMZ (100μM) or AraC (1μM)

**D**

CONTROL  | AraC 1μM  | TMZ 100μM
---|---|---

**E**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>% Ki67</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cont (DMSO)</td>
<td>30 ± 3</td>
</tr>
<tr>
<td>AraC 1μM</td>
<td>10 ± 5 *</td>
</tr>
<tr>
<td>TMZ 100μM</td>
<td>5 ± 2 *</td>
</tr>
</tbody>
</table>

**F**

CONTROL  | AraC 1μM  | TMZ 100μM
---|---|---

**G**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>% Active-caspase3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cont (DMSO)</td>
<td>5 ± 1 *</td>
</tr>
<tr>
<td>AraC 1μM</td>
<td>20 ± 2 **</td>
</tr>
<tr>
<td>TMZ 100μM</td>
<td>30 ± 3 **</td>
</tr>
</tbody>
</table>

**H**

CONTROL  | AraC 1μM  | TMZ 100μM
---|---|---
Figure 5 | Temozolomide and Ara-C treatment of slice co-cultures. (A) DNA damage responses of mouse IENS-GFP cells following treatment various doses of antimitotic agents AraC and TMZ. Immunocytochemistry for γH2AX (yellow) and p53 (red). Nuclear counterstaining DAPI (blue) (B) Quantitation of mean intensity of the nuclear H2AX foci (arbitrary units). Schematics of the co-culture of IENS-GFP cells in the brain slices adding pharmacological inhibitors of the proliferation. (D) Immunostaining for GFP (green) and Ki67 (magenta) with DAPI (blue) for nuclear counterstaining (E) Quantification of the percentage of Ki67 (proliferative cells) using the proliferative inhibitors in IENS-GFP after 24 hours. (F) Immunocytochemistry for GFP (green) and pHH3 (mitotic cells) (red) in IENS-GFP after treatments. Percentage of pHH3 positive cells are in red typing. Scale bars 20µm. (G) Quantification of percentage of active caspase3 in the IENS-GFP cells after the treatments with AraC and TMZ. (H) Immunostaining for active caspase3 in the IENS-GFP cells in the brain slices after treatments. Scale bars in (A) 10 µm, (D), (F), (H) 30 µm. N=3, Students t-test p<0.01 in E and N=3, Students t-test p< 0.05.
Supplementary Figure 1. (A) Immunostaining for GFAP (red) and Ki67 (magenta) of IENS-GFP cells deposited in the brain slices with complete media with/without serum. (B) Quantification of the percentage of cells positive for GFAP and Ki67. (C) PI staining in brain slices after 24 hours. Slices were cultured with DMEM-F12 or with complete media. Scale bar in A: 30 µm. N=3, Students t-test p<0.01.
Supplementary Figure 2. IENS-GFP cells on the brain tissue in complete media or complete media supplemented with serum after 5 days (A) Immunostaining of GFAP (red) and KI67 (magenta) in IENS-GFP. (B) Quantification of the percentage of KI67 and GFAP positive cells. Scale bar in A: 20 µm.
Supplementary Figure 3. (A) G7 cells in vitro. Immunostaining for different markers in vitro. Ki67 (red), Olig2 (red), Sox2 (red), Nestin (yellow), CD9 (red), CD133 (red).

Scale bar: A = 20 µm